Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
Single-Cell Phenotypic Characterization of Human Pituitary GHomas and Non-Functioning Adenomas Based on Hormone Content and Calcium Responses to Hypothalamic Releasing Hormones.

Frontiers in oncology

Senovilla L, Núñez L, de Campos JM, de Luis DA, Romero E, García-Sancho J, Villalobos C.
PMID: 26106585
Front Oncol. 2015 Jun 09;5:124. doi: 10.3389/fonc.2015.00124. eCollection 2015.

Human pituitary tumors are generally benign adenomas causing considerable morbidity due to excess hormone secretion, hypopituitarism, and other tumor mass effects. Pituitary tumors are highly heterogeneous and difficult to type, often containing mixed cell phenotypes. We have used calcium...

Cite
Senovilla L, Núñez L, de Campos JM, et al. Single-Cell Phenotypic Characterization of Human Pituitary GHomas and Non-Functioning Adenomas Based on Hormone Content and Calcium Responses to Hypothalamic Releasing Hormones. Front Oncol. 2015;5:124doi: 10.3389/fonc.2015.00124.
Senovilla, L., Núñez, L., de Campos, J. M., de Luis, D. A., Romero, E., García-Sancho, J., & Villalobos, C. (2015). Single-Cell Phenotypic Characterization of Human Pituitary GHomas and Non-Functioning Adenomas Based on Hormone Content and Calcium Responses to Hypothalamic Releasing Hormones. Frontiers in oncology, 5124. https://doi.org/10.3389/fonc.2015.00124
Senovilla, Laura, et al. "Single-Cell Phenotypic Characterization of Human Pituitary GHomas and Non-Functioning Adenomas Based on Hormone Content and Calcium Responses to Hypothalamic Releasing Hormones." Frontiers in oncology vol. 5 (2015): 124. doi: https://doi.org/10.3389/fonc.2015.00124
Senovilla L, Núñez L, de Campos JM, de Luis DA, Romero E, García-Sancho J, Villalobos C. Single-Cell Phenotypic Characterization of Human Pituitary GHomas and Non-Functioning Adenomas Based on Hormone Content and Calcium Responses to Hypothalamic Releasing Hormones. Front Oncol. 2015 Jun 09;5:124. doi: 10.3389/fonc.2015.00124. eCollection 2015. PMID: 26106585; PMCID: PMC4460876.
Copy Download .nbib Format: NLM
Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease.

Aging and disease

Maeso-Díaz R, Ortega-Ribera M, Lafoz E, Lozano JJ, Baiges A, Francés R, Albillos A, Peralta C, García-Pagán JC, Bosch J, Cogger VC, Gracia-Sancho J.
PMID: 31440376
Aging Dis. 2019 Aug 01;10(4):684-698. doi: 10.14336/AD.2019.0127. eCollection 2019 Aug.

Advanced chronic liver disease (aCLD) represents a major public health concern. aCLD is more prevalent and severe in the elderly, carrying a higher risk of decompensation. We aimed at understanding how aging may impact on the pathophysiology of aCLD...

Cite
Maeso-Díaz R, Ortega-Ribera M, Lafoz E, et al. Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. Aging Dis. 2019;10(4):684-698doi: 10.14336/AD.2019.0127.
Maeso-Díaz, R., Ortega-Ribera, M., Lafoz, E., Lozano, J. J., Baiges, A., Francés, R., Albillos, A., Peralta, C., García-Pagán, J. C., Bosch, J., Cogger, V. C., & Gracia-Sancho, J. (2019). Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. Aging and disease, 10(4), 684-698. https://doi.org/10.14336/AD.2019.0127
Maeso-Díaz, Raquel, et al. "Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease." Aging and disease vol. 10,4 (2019): 684-698. doi: https://doi.org/10.14336/AD.2019.0127
Maeso-Díaz R, Ortega-Ribera M, Lafoz E, Lozano JJ, Baiges A, Francés R, Albillos A, Peralta C, García-Pagán JC, Bosch J, Cogger VC, Gracia-Sancho J. Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. Aging Dis. 2019 Aug 01;10(4):684-698. doi: 10.14336/AD.2019.0127. eCollection 2019 Aug. PMID: 31440376; PMCID: PMC6675529.
Copy Download .nbib Format: NLM
Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature.

Cancers

Manicardi N, Fernández-Iglesias A, Abad-Jordà L, Royo F, Azkargorta M, Ortega-Ribera M, Sanfeliu-Redondo D, Martínez-Alcocer A, Elortza F, Hessheimer AJ, Fondevila C, Lozano JJ, García-Pagán JC, Bosch J, Cubero FJ, Albillos A, Vaquero J, Falcón-Pérez JM, Gracia-Sancho J.
PMID: 34072510
Cancers (Basel). 2021 May 29;13(11). doi: 10.3390/cancers13112688.

The poor prognosis of chronic liver disease (CLD) generates the need to investigate the evolving mechanisms of disease progression, thus disclosing therapeutic targets before development of clinical complications. Considering the central role of liver sinusoidal endothelial cells (LSECs) in...

Cite
Manicardi N, Fernández-Iglesias A, Abad-Jordà L, et al. Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. Cancers (Basel). 2021;13(11)doi: 10.3390/cancers13112688.
Manicardi, N., Fernández-Iglesias, A., Abad-Jordà, L., Royo, F., Azkargorta, M., Ortega-Ribera, M., Sanfeliu-Redondo, D., Martínez-Alcocer, A., Elortza, F., Hessheimer, A. J., Fondevila, C., Lozano, J. J., García-Pagán, J. C., Bosch, J., Cubero, F. J., Albillos, A., Vaquero, J., Falcón-Pérez, J. M., & Gracia-Sancho, J. (2021). Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. Cancers, 13(11), . https://doi.org/10.3390/cancers13112688
Manicardi, Nicolò, et al. "Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature." Cancers vol. 13,11 (2021). doi: https://doi.org/10.3390/cancers13112688
Manicardi N, Fernández-Iglesias A, Abad-Jordà L, Royo F, Azkargorta M, Ortega-Ribera M, Sanfeliu-Redondo D, Martínez-Alcocer A, Elortza F, Hessheimer AJ, Fondevila C, Lozano JJ, García-Pagán JC, Bosch J, Cubero FJ, Albillos A, Vaquero J, Falcón-Pérez JM, Gracia-Sancho J. Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. Cancers (Basel). 2021 May 29;13(11). doi: 10.3390/cancers13112688. PMID: 34072510; PMCID: PMC8198220.
Copy Download .nbib Format: NLM
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.

Journal of hepatology

Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J.
PMID: 33278455
J Hepatol. 2021 May;74(5):1188-1199. doi: 10.1016/j.jhep.2020.11.045. Epub 2020 Dec 02.

BACKGROUND & AIMS: In advanced chronic liver disease (ACLD), deregulated hepatic necroinflammatory processes play a key role in the development of liver microvascular dysfunction, fibrogenesis, and increased hepatic vascular tone, resulting in progression of ACLD and portal hypertension. Given...

Cite
Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2020;74(5):1188-1199doi: 10.1016/j.jhep.2020.11.045.
Boyer-Diaz, Z., Aristu-Zabalza, P., Andrés-Rozas, M., Robert, C., Ortega-Ribera, M., Fernández-Iglesias, A., Broqua, P., Junien, J. L., Wettstein, G., Bosch, J., & Gracia-Sancho, J. (2021). Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. Journal of hepatology, 74(5), 1188-1199. https://doi.org/10.1016/j.jhep.2020.11.045
Boyer-Diaz, Zoe, et al. "Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease." Journal of hepatology vol. 74,5 (2021): 1188-1199. doi: https://doi.org/10.1016/j.jhep.2020.11.045
Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2021 May;74(5):1188-1199. doi: 10.1016/j.jhep.2020.11.045. Epub 2020 Dec 02. PMID: 33278455.
Copy Download .nbib Format: NLM
Advances in therapeutic options for portal hypertension.

Therapeutic advances in gastroenterology

Vilaseca M, Guixé-Muntet S, Fernández-Iglesias A, Gracia-Sancho J.
PMID: 30505350
Therap Adv Gastroenterol. 2018 Nov 25;11:1756284818811294. doi: 10.1177/1756284818811294. eCollection 2018.

Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact on patients' prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its...

Cite
Vilaseca M, Guixé-Muntet S, Fernández-Iglesias A, et al. Advances in therapeutic options for portal hypertension. Therap Adv Gastroenterol. 2018;11:1756284818811294doi: 10.1177/1756284818811294.
Vilaseca, M., Guixé-Muntet, S., Fernández-Iglesias, A., & Gracia-Sancho, J. (2018). Advances in therapeutic options for portal hypertension. Therapeutic advances in gastroenterology, 111756284818811294. https://doi.org/10.1177/1756284818811294
Vilaseca, Marina, et al. "Advances in therapeutic options for portal hypertension." Therapeutic advances in gastroenterology vol. 11 (2018): 1756284818811294. doi: https://doi.org/10.1177/1756284818811294
Vilaseca M, Guixé-Muntet S, Fernández-Iglesias A, Gracia-Sancho J. Advances in therapeutic options for portal hypertension. Therap Adv Gastroenterol. 2018 Nov 25;11:1756284818811294. doi: 10.1177/1756284818811294. eCollection 2018. PMID: 30505350; PMCID: PMC6256317.
Copy Download .nbib Format: NLM
Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis.

Journal of translational medicine

Lamo-Espinosa JM, Prósper F, Blanco JF, Sánchez-Guijo F, Alberca M, García V, González-Vallinas M, García-Sancho J.
PMID: 34895259
J Transl Med. 2021 Dec 11;19(1):506. doi: 10.1186/s12967-021-03160-2.

Knee osteoarthritis is the most prevalent joint disease and a frequent cause of pain, functional loss and disability. Conventional treatments have demonstrated only modest clinical benefits whereas cell-based therapies have shown encouraging results, but important details, such as dose...

Cite
Lamo-Espinosa JM, Prósper F, Blanco JF, et al. Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis. J Transl Med. 2021;19(1):506doi: 10.1186/s12967-021-03160-2.
Lamo-Espinosa, J. M., Prósper, F., Blanco, J. F., Sánchez-Guijo, F., Alberca, M., García, V., González-Vallinas, M., & García-Sancho, J. (2021). Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis. Journal of translational medicine, 19(1), 506. https://doi.org/10.1186/s12967-021-03160-2
Lamo-Espinosa, José María, et al. "Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis." Journal of translational medicine vol. 19,1 (2021): 506. doi: https://doi.org/10.1186/s12967-021-03160-2
Lamo-Espinosa JM, Prósper F, Blanco JF, Sánchez-Guijo F, Alberca M, García V, González-Vallinas M, García-Sancho J. Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis. J Transl Med. 2021 Dec 11;19(1):506. doi: 10.1186/s12967-021-03160-2. PMID: 34895259; PMCID: PMC8666077.
Copy Download .nbib Format: NLM
Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities.

Pharmacology & therapeutics

Azparren-Angulo M, Royo F, Gonzalez E, Liebana M, Brotons B, Berganza J, Goñi-de-Cerio F, Manicardi N, Abad-Jordà L, Gracia-Sancho J, Falcon-Perez JM.
PMID: 32961265
Pharmacol Ther. 2021 Feb;218:107683. doi: 10.1016/j.pharmthera.2020.107683. Epub 2020 Sep 19.

Since the first descriptions of hepatocyte-released exosome-like vesicles in 2008, the number of publications describing Extracellular Vesicles (EVs) released by liver cells in the context of hepatic physiology and pathology has grown exponentially. This growing interest highlights both the...

Cite
Azparren-Angulo M, Royo F, Gonzalez E, et al. Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities. Pharmacol Ther. 2020;218:107683doi: 10.1016/j.pharmthera.2020.107683.
Azparren-Angulo, M., Royo, F., Gonzalez, E., Liebana, M., Brotons, B., Berganza, J., Goñi-de-Cerio, F., Manicardi, N., Abad-Jordà, L., Gracia-Sancho, J., & Falcon-Perez, J. M. (2021). Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities. Pharmacology & therapeutics, 218107683. https://doi.org/10.1016/j.pharmthera.2020.107683
Azparren-Angulo, Maria, et al. "Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities." Pharmacology & therapeutics vol. 218 (2021): 107683. doi: https://doi.org/10.1016/j.pharmthera.2020.107683
Azparren-Angulo M, Royo F, Gonzalez E, Liebana M, Brotons B, Berganza J, Goñi-de-Cerio F, Manicardi N, Abad-Jordà L, Gracia-Sancho J, Falcon-Perez JM. Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities. Pharmacol Ther. 2021 Feb;218:107683. doi: 10.1016/j.pharmthera.2020.107683. Epub 2020 Sep 19. PMID: 32961265.
Copy Download .nbib Format: NLM
Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism.

Hepatology communications

Gracia-Sancho J, Manicardi N, Ortega-Ribera M, Maeso-Díaz R, Guixé-Muntet S, Fernández-Iglesias A, Hide D, García-Calderó H, Boyer-Díaz Z, Contreras PC, Spada A, Bosch J.
PMID: 31304452
Hepatol Commun. 2019 Apr 22;3(7):987-1000. doi: 10.1002/hep4.1360. eCollection 2019 Jul.

In cirrhosis, liver microvascular dysfunction is a key factor increasing hepatic vascular resistance to portal blood flow, which leads to portal hypertension. De-regulated inflammatory and pro-apoptotic processes due to chronic injury play important roles in the dysfunction of liver...

Cite
Gracia-Sancho J, Manicardi N, Ortega-Ribera M, et al. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatol Commun. 2019;3(7):987-1000doi: 10.1002/hep4.1360.
Gracia-Sancho, J., Manicardi, N., Ortega-Ribera, M., Maeso-Díaz, R., Guixé-Muntet, S., Fernández-Iglesias, A., Hide, D., García-Calderó, H., Boyer-Díaz, Z., Contreras, P. C., Spada, A., & Bosch, J. (2019). Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatology communications, 3(7), 987-1000. https://doi.org/10.1002/hep4.1360
Gracia-Sancho, Jordi, et al. "Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism." Hepatology communications vol. 3,7 (2019): 987-1000. doi: https://doi.org/10.1002/hep4.1360
Gracia-Sancho J, Manicardi N, Ortega-Ribera M, Maeso-Díaz R, Guixé-Muntet S, Fernández-Iglesias A, Hide D, García-Calderó H, Boyer-Díaz Z, Contreras PC, Spada A, Bosch J. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatol Commun. 2019 Apr 22;3(7):987-1000. doi: 10.1002/hep4.1360. eCollection 2019 Jul. PMID: 31304452; PMCID: PMC6601324.
Copy Download .nbib Format: NLM
Automatic Liver Viability Scoring with Deep Learning and Hyperspectral Imaging.

Diagnostics (Basel, Switzerland)

Felli E, Al-Taher M, Collins T, Nkusi R, Felli E, Baiocchini A, Lindner V, Vincent C, Barberio M, Geny B, Ettorre GM, Hostettler A, Mutter D, Gioux S, Schuster C, Marescaux J, Gracia-Sancho J, Diana M.
PMID: 34573869
Diagnostics (Basel). 2021 Aug 24;11(9). doi: 10.3390/diagnostics11091527.

Hyperspectral imaging (HSI) is a non-invasive imaging modality already applied to evaluate hepatic oxygenation and to discriminate different models of hepatic ischemia. Nevertheless, the ability of HSI to detect and predict the reperfusion damage intraoperatively was not yet assessed....

Cite
Felli E, Al-Taher M, Collins T, et al. Automatic Liver Viability Scoring with Deep Learning and Hyperspectral Imaging. Diagnostics (Basel). 2021;11(9)doi: 10.3390/diagnostics11091527.
Felli, E., Al-Taher, M., Collins, T., Nkusi, R., Felli, E., Baiocchini, A., Lindner, V., Vincent, C., Barberio, M., Geny, B., Ettorre, G. M., Hostettler, A., Mutter, D., Gioux, S., Schuster, C., Marescaux, J., Gracia-Sancho, J., & Diana, M. (2021). Automatic Liver Viability Scoring with Deep Learning and Hyperspectral Imaging. Diagnostics (Basel, Switzerland), 11(9), . https://doi.org/10.3390/diagnostics11091527
Felli, Eric, et al. "Automatic Liver Viability Scoring with Deep Learning and Hyperspectral Imaging." Diagnostics (Basel, Switzerland) vol. 11,9 (2021). doi: https://doi.org/10.3390/diagnostics11091527
Felli E, Al-Taher M, Collins T, Nkusi R, Felli E, Baiocchini A, Lindner V, Vincent C, Barberio M, Geny B, Ettorre GM, Hostettler A, Mutter D, Gioux S, Schuster C, Marescaux J, Gracia-Sancho J, Diana M. Automatic Liver Viability Scoring with Deep Learning and Hyperspectral Imaging. Diagnostics (Basel). 2021 Aug 24;11(9). doi: 10.3390/diagnostics11091527. PMID: 34573869; PMCID: PMC8472457.
Copy Download .nbib Format: NLM
Subcellular Ca(2+) Dynamics.

News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society

Alvarez J, Montero M, García-Sancho J.
PMID: 11390843
News Physiol Sci. 1999 Aug;14:161-168.

The field of subcellular Ca(2+) homeostasis is evolving rapidly. In parallel with improvements in spatial and temporal resolution of Ca(2+) imaging techniques, new methods using the natural cell machinery to target Ca(2+)-sensitive proteins such as aequorin to precise intracellular...

Cite
Alvarez J, Montero M, García-Sancho J. Subcellular Ca(2+) Dynamics. News Physiol Sci. 1999;14:161-168
Alvarez, J., Montero, M., & García-Sancho, J. (1999). Subcellular Ca(2+) Dynamics. News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society, 14161-168.
Alvarez, Javier, et al. "Subcellular Ca(2+) Dynamics." News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society vol. 14 (1999): 161-168.
Alvarez J, Montero M, García-Sancho J. Subcellular Ca(2+) Dynamics. News Physiol Sci. 1999 Aug;14:161-168. PMID: 11390843.
Copy Download .nbib Format: NLM
Mechanisms of portal hypertension: Bench to bedside.

Clinical liver disease

Gracia-Sancho J, Laleman W.
PMID: 31041086
Clin Liver Dis (Hoboken). 2016 Dec 30;8(6):160-166. doi: 10.1002/cld.604. eCollection 2016 Dec.

No abstract available.

Cite
Gracia-Sancho J, Laleman W. Mechanisms of portal hypertension: Bench to bedside. Clin Liver Dis (Hoboken). 2016;8(6):160-166doi: 10.1002/cld.604.
Gracia-Sancho, J., & Laleman, W. (2016). Mechanisms of portal hypertension: Bench to bedside. Clinical liver disease, 8(6), 160-166. https://doi.org/10.1002/cld.604
Gracia-Sancho, Jordi, and Laleman, Wim. "Mechanisms of portal hypertension: Bench to bedside." Clinical liver disease vol. 8,6 (2016): 160-166. doi: https://doi.org/10.1002/cld.604
Gracia-Sancho J, Laleman W. Mechanisms of portal hypertension: Bench to bedside. Clin Liver Dis (Hoboken). 2016 Dec 30;8(6):160-166. doi: 10.1002/cld.604. eCollection 2016 Dec. PMID: 31041086; PMCID: PMC6490242.
Copy Download .nbib Format: NLM
Limited Joint Mobility Progression in Type 1 Diabetes: A 15-Year Follow-Up Study.

International journal of endocrinology

Labad J, Rozadilla A, Garcia-Sancho P, Nolla JM, Montanya E.
PMID: 29853876
Int J Endocrinol. 2018 May 02;2018:1897058. doi: 10.1155/2018/1897058. eCollection 2018.

OBJECTIVE: To assess the evolution of joint mobility over a period of 15 years in type 1 diabetic patients and healthy controls and to determine whether microalbuminuria is associated with a different evolution of joint mobility.METHODS: Joint mobility of...

Cite
Labad J, Rozadilla A, Garcia-Sancho P, et al. Limited Joint Mobility Progression in Type 1 Diabetes: A 15-Year Follow-Up Study. Int J Endocrinol. 2018;2018:1897058doi: 10.1155/2018/1897058.
Labad, J., Rozadilla, A., Garcia-Sancho, P., Nolla, J. M., & Montanya, E. (2018). Limited Joint Mobility Progression in Type 1 Diabetes: A 15-Year Follow-Up Study. International journal of endocrinology, 20181897058. https://doi.org/10.1155/2018/1897058
Labad, Javier, et al. "Limited Joint Mobility Progression in Type 1 Diabetes: A 15-Year Follow-Up Study." International journal of endocrinology vol. 2018 (2018): 1897058. doi: https://doi.org/10.1155/2018/1897058
Labad J, Rozadilla A, Garcia-Sancho P, Nolla JM, Montanya E. Limited Joint Mobility Progression in Type 1 Diabetes: A 15-Year Follow-Up Study. Int J Endocrinol. 2018 May 02;2018:1897058. doi: 10.1155/2018/1897058. eCollection 2018. PMID: 29853876; PMCID: PMC5954902.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries